Australia's Island Pharmaceuticals hits record low on clinical material making delay
15/06/2022 05:31
** Shares of drug develop Island Pharmaceuticals ILA.AX
slide as much as 18.8% to their all-time low of A$0.130
** Co executes a new, one-off, proposal with Sofgen
Pharmaceuticals for the manufacture of its ISLA-101 clinical
material for treatment of dengue urn:newsml:reuters.com:*:nASX7vz4Hy
** Says the new proposal outlines manufacture of ISLA-101
clinical material in mid-August, a six-week delay from previous
estimates
** Expects that the investigational new drug application
will be filed in October, with the clinical trial commencing in
November
** Shares mark their worst intraday pct fall since June 10
** As of last close, stock down 37.3% this year
(Reporting by Himanshi Akhand in Bengaluru)
((Himanshi.Akhand@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic